Justice Department Final Rule

2026-12653: Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction

Get alerted when the next rule lands

New rules open for comment on their own schedule. Pick how you want to hear about them — we email you when one appears.

Alert me on new Justice Department rules or alert me on a subject

Publishing to members? Embed a live rule tracker on your own site — the proposed rules in your area and the comment deadlines closing on them, updating themselves. Free, one line of HTML.

Create a free account & build one →

Summary

On March 16, 2026, the Drug Enforcement Administration published a temporary order placing 8-bromo-1-methyl-6-phenyl-4H- benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. DEA published this temporary order that included an invalid chemical name for bromazolam. This document corrects that error, adding the valid chemical name for bromazolam.

The agency’s own summary, as published.

The rule, in full

488 words as published, June 24, 2026. View the original →

Federal Register, Volume 91 Issue 120 (Wednesday, June 24, 2026) [Federal Register Volume 91, Number 120 (Wednesday, June 24, 2026)] [Rules and Regulations] [Pages 37821-37822] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2026-12653] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-1420] Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction

Agency

Drug Enforcement Administration, Department of Justice.

Action

Correcting amendment. -----------------------------------------------------------------------

Summary

On March 16, 2026, the Drug Enforcement Administration published a temporary order placing 8-bromo-1-methyl-6-phenyl-4H- benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. DEA published this temporary order that included an invalid chemical name for bromazolam. This document corrects that error, adding the valid chemical name for bromazolam.

Dates

This correcting amendment is effective June 24, 2026, and applicable beginning March 16, 2026.

For Further Information Contact

Dr. Terrence L. Boos, Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration; Telephone: (571) 362-3249. [[Page 37822]]

Supplementary Information

The placement of bromazolam under schedule I was effective on March 16, 2026.\1\ After publication of the temporary scheduling order, DEA included an invalid chemical name for bromazolam as 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine. This document corrects the chemical name for bromazolam as 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3- a][1,4]diazepine. --------------------------------------------------------------------------- \1\ Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I, 91 FR 12504 (Mar. 16, 2026). --------------------------------------------------------------------------- List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements. For the reasons set out above, DEA corrects 21 CFR part 1308 with the following correcting amendment: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0

1. The authority citation for part 1308 continues to read as follows:

Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise noted. 0

2. In Sec. 1308.11 revise paragraph (h)(86) to read as follows:

Sec. 1308.11 Schedule I. * * * * * (h) * * * ------------------------------------------------------------------------ ------------------------------------------------------------------------ * * * * * * * (86) 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3- 2778 a][1,4]diazepine, its salts, isomers, and salts of isomers (Other name: bromazolam)...................................... * * * * * * * ------------------------------------------------------------------------ Signing Authority This document of the Drug Enforcement Administration was signed on June 16, 2026, by DEA Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the Federal Register. Heather Achbach, Federal Register Liaison Officer, Drug Enforcement Administration. [FR Doc. 2026-12653 Filed 6-23-26; 8:45 am] BILLING CODE 4410-09-P

What this changes

Amends 1 part of the Code of Federal Regulations — the standing rules this notice rewrites.

Don't miss the comment window

One Click Politics alerts you on every deadline, hearing, and rule change.

See all rules with comments due soon →